Naloxone Access
Getting naloxone where it is needed most
Naloxone is an affordable, safe, and life-saving medicine — but naloxone only prevents overdose deaths when it is widely accessible and in the hands of people who are witnessing overdoses.
People most likely to witness overdose are people who use drugs and our loved ones and social networks. People who use drugs and are unhoused or leaving incarceration are even more likely to witness an overdose.
Yet, for far too long, naloxone has been kept behind pharmacy doors or prioritized for first responders. The United States lags behind many nations in widespread naloxone distribution, and New Jersey lags behind many states.
We champion policies that remove legal and administrative barriers to community naloxone distribution, and for public funding to prioritize widespread community-based distribution.
Learn more about New Jersey's updated naloxone law from News12 — featuring Caitlin O'Neill
Latest
Co-Prescribed Naloxone
July 1, 2021
Frequently Asked Questions About Co-Prescribed Naloxone Why am I being
NJHRC: Gov. Murphy’s Opioid Announcement Shows Urgency of Harm Reduction Expansion
March 4, 2021
Earlier today, Governor Murphy announced 3,040 overdose deaths in 2020
Learn More
- Statement on Continued Efforts to Increase Availability of All Forms of Naloxone to Help Reduce Opioid Overdose Deaths [FDA]
- Research on Efficacy of Delivering Naloxone Directly to People Who Use Drugs [Remedy Alliance FTP]
- Harm Reduction Programs Distribute One Million Doses of Naloxone in 2019 [Eliza Wheeler & Maya Doe-Simpkins]
Donate Now
Harm reduction is essential. A harm reduction approach to drug use is the best strategy we have to end the overdose crisis, reduce risks associated with drug use, and affirm the dignity and bodily autonomy of every New Jerseyan.
